Evaxion A/S (EVAX) income statement
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.54−0.24 (-8.63%)
Close on Nov 18, 2026Market cap $21.18MP/E –Yield –
Evaxion A/S income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -122.7%
- Net margin
- -102.4%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 5.06
- Debt to equity
- –
- Debt to assets
- 27.4%
- Cash to current liabilities
- 446.9%
Valuation
- P/E ratio
- –
- Price to sales
- 2.81
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?